Skip to main content


Editor's pick

Intravitreal injection linked to substantial temporary blood pressure increase


Patients undergoing intravitreal injections with anti–vascular endothelial growth factor agents can experience substantial transient increases in systolic blood pressure, Swiss researchers report.

06-12-2018 | Ophthalmology | News | Article

SRF tolerant ranibizumab regimen does not negatively impact visual outcomes

Tolerating some subretinal fluid during a treat-and-extend ranibizumab protocol does not detrimentally affect visual acuity in patients with neovascular age-related macular degeneration, study findings indicate.


Ophthalmol 2018; doi:10.1016/j.ophtha.2018.11.025

29-11-2018 | Ophthalmology | News | Article

Treatment-related non-fibrotic scars do not negatively affect vision

Developing non-fibrotic scars during the first year of anti-vascular endothelial growth factor treatment does not have a detrimental effect on visual acuity during the following 4 years, US researchers report.


Ophthalmology 2018; doi:10.1016/j.ophtha.2018.11.020

22-11-2018 | Ophthalmology | News | Article

Fixed-combination BBFC improves 24-hour intraocular pressure after 4 weeks

Treatment with fixed-combination brinzolamide 1%/brimonidine 0.2% for 4 weeks significantly reduces 24-hour intraocular pressure in patients with open-angle glaucoma or ocular hypertension, US researchers report.


Ophthalmol 2018; doi:10.1016/j.ophtha.2018.10.040

15-11-2018 | Ophthalmology | News | Article

Current glaucoma staging systems underestimate disease severity

Current glaucoma staging systems based on 24-2 (or 30-2) visual fields underestimate disease severity and the presence of macular damage when compared with 10-2 visual fields and high-resolution macular imaging, US researchers report.


JAMA Ophthalmol 2018; doi:10.1001/jamaophthalmol.2018.5398

Twitter Icon Follow medwireNews

Click here
image credits